A case report of individualized treatment of high risk and volume metastatic prostate cancer

唐琦,米悦,虞巍,何志嵩,宋毅,杨恺惟
DOI: https://doi.org/10.3760/cma.j.cn112330-20210405-00005
2021-01-01
Abstract:A 69-year old man presented with high-risk metastatic prostate cancer. After 7 months of androgen deprivation therapy (ADT), he progressed to metastatic castration resistant prostate cancer. We suggested him comprehensive therapy, including Abiraterone, chemo-therapy, radio-therapy, platinum chemo-therapy and Enzalutamide, which proved effective with his long term survival.
What problem does this paper attempt to address?